Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 885 entries
View as:

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04606381 Org: User:
Start: 11/10/20 End: 04/30/27 Due: 04/30/28

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Phase: N/A Priority: Normal
NCT ID: NCT02854436 Org: User:
Start: 08/31/16 End: 08/16/23 Due: 08/16/24

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

Phase: N/A Priority: Normal
NCT ID: NCT03479736 Org: User:
Start: 11/20/17 End: 06/04/18 Due: 06/04/19

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Phase: N/A Priority: Normal
NCT ID: NCT03492580 Org: User:
Start: 02/22/18 End: 06/25/18 Due: 06/25/19

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT04667104 Org: User:
Start: 02/01/21 End: 04/17/23 Due: 04/17/24

A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics

Phase: N/A Priority: Normal
NCT ID: NCT02470481 Org: User:
Start: 03/31/15 End: 07/31/16 Due: 07/31/17

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01862224 Org: User:
Start: 07/31/13 End: 07/31/14 Due: 07/31/15

A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men

Phase: N/A Priority: Normal
NCT ID: NCT01575587 Org: User:
Start: 01/31/12 End: 05/31/12 Due: 05/31/13

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

Phase: N/A Priority: Normal
NCT ID: NCT02207244 Org: User:
Start: 11/03/14 End: 07/01/20 Due: 07/01/21

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

Phase: N/A Priority: Normal
NCT ID: NCT01964651 Org: User:
Start: 10/31/13 End: 10/31/14 Due: 10/31/15

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

Phase: N/A Priority: Normal
NCT ID: NCT01442532 Org: User:
Start: 09/30/11 End: 07/31/12 Due: 07/31/13

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03346122 Org: User:
Start: 11/15/17 End: 11/20/18 Due: 11/20/19

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03301220 Org: User:
Start: 11/07/17 End: 12/11/25 Due: 12/11/26

A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01597739 Org: User:
Start: 07/31/12 End: 04/30/13 Due: 04/30/14

Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT01323205 Org: User:
Start: 05/31/11 End: 12/31/12 Due: 12/31/13

Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT02821858 Org: User:
Start: 06/14/16 End: 09/30/16 Due: 09/30/17

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04210219 Org: User:
Start: 07/02/20 End: 05/28/25 Due: 05/28/26

A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT01274507 Org: User:
Start: 07/31/10 End: 07/31/14 Due: 07/31/15

A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT02260700 Org: User:
Start: 09/30/13 End: 11/30/13 Due: 11/30/14

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

Phase: N/A Priority: Normal
NCT ID: NCT01309438 Org: User:
Start: 02/28/11 End: 03/31/12 Due: 03/31/13

Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

Phase: N/A Priority: Normal
NCT ID: NCT03945903 Org: User:
Start: - End: - Due: -

A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02051738 Org: User:
Start: 02/28/14 End: 04/30/14 Due: 04/30/15

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT01273389 Org: User:
Start: 08/31/11 End: 09/30/13 Due: 09/30/14

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT01273493 Org: User:
Start: 12/31/10 End: 04/30/14 Due: 04/30/15

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03551782 Org: User:
Start: 06/28/18 End: 11/11/21 Due: 11/11/22